Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E9JR
|
|||
| Former ID |
DNC009409
|
|||
| Drug Name |
Ethyl 2-cyano-2-(quinoxalin-2(1H)-ylidene)acetate
|
|||
| Synonyms |
AC1NVSSE; MLS000104229; CHEMBL3197417; MolPort-002-136-693; MolPort-019-735-612; HMS2400I13; CCG-2361; ZINC18045921; STL321690; AKOS022107323; SMR000051278; SR-01000198931; SR-01000198931-1; ethyl (2Z)-cyano(quinoxalin-2(1H)-ylidene)ethanoate; ethyl (2Z)-2-cyano-2-(1H-quinoxalin-2-ylidene)acetate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H11N3O2
|
|||
| Canonical SMILES |
CCOC(=O)C(C#N)C1=NC2=CC=CC=C2N=C1
|
|||
| InChI |
1S/C13H11N3O2/c1-2-18-13(17)9(7-14)12-8-15-10-5-3-4-6-11(10)16-12/h3-6,8-9H,2H2,1H3
|
|||
| InChIKey |
KKQBQZXMEPUMLX-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Matrix metalloproteinase-13 (MMP-13) | Target Info | Inhibitor | [1] |
| NetPath Pathway | IL1 Signaling Pathway | |||
| Panther Pathway | Alzheimer disease-presenilin pathway | |||
| Plasminogen activating cascade | ||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| Assembly of collagen fibrils and other multimeric structures | ||||
| WikiPathways | Endochondral Ossification | |||
| Activation of Matrix Metalloproteinases | ||||
| Oncostatin M Signaling Pathway | ||||
| AGE/RAGE pathway | ||||
| Matrix Metalloproteinases | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.